SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Board appointments

31 Mar 2014 07:00

RNS Number : 5183D
Frontier IP Group plc
31 March 2014
 



 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Company")

 

Board changes

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce two Board appointments, which both take immediate effect. James Fish has been appointed to the Company as Finance Director and Michael Bourne has been appointed to the Company as a Non-Executive Director.

 

James Fish, a chartered accountant, has over 25 years' experience in senior financial positions and a wide range of commercial experience including venture capital funded small/medium-sized enterprises and start-up companies. He was latterly interim Finance Director at The One Place Capital Limited, an online technology start-up. He qualified as a chartered accountant with KPMG and holds a degree in Accounting and Finance from Heriot Watt University, Edinburgh. James's appointment enables Marilyn Cole to step down as Finance Director and Company Secretary. James will also be appointed Company Secretary.

 

Michael Bourne has almost 30 years' experience in investment management and particular expertise in technology, life sciences and clean technology. He is currently Partner of Accretion Capital LLP and a Director of Cygna Negra Limited and Cygna Negra Malta Limited. He is also an Advisory Board Member of V2R, the US technology transfer venture company. Prior to these roles, in 1995, he founded asset management company, Reabourne Technology Investments Limited, where he was also Chief Investment Officer. For nine years until 2009, he was also a member of the techMARK Advisory Committee.

 

Neil Crabb, Chief Executive of Frontier IP, said,

 

"We are delightedto welcome Jim as Finance Director and Mike as a Non-executive Director. Their appointments strengthen our Board as we continue Frontier IP's development.

 

Jim brings over 25 years' experience as a senior finance professional and his involvement with start-up companies as well as venture capital funded SMEs is especially useful. Mike has substantial experience in investment management and his expertise in the clean energy and life sciences sectors also represents an excellent fit with Frontier IP's activities.

 

As well as welcoming Jim and Mike, I would also like to acknowledge Marilyn's significant contribution to Frontier IP during her time as Finance Director of the Company. She leaves with the Board's best wishes and grateful thanks."

 

The following information is required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

James Milne Fish, aged 56, is or has been a director or partner of the following companies during the previous five years:

 

Current Directorships / Partnerships:

Directorships / Partnerships held within the previous five years:

FD Support Limited

 

In addition, as an interim finance director, Mr Fish has undertaken in the previous five years a finance director role with The One Place Capital Limited, McLaren Software Group Limited and Photo Therapeutics Group Limited. Photo Therapeutics Group Limited entered into a Voluntary Members Liquidation in March 2009, after the return of funds to shareholders following a trade sale of the operating subsidiary.

 

Mr Fish is a member of the Institute of Chartered Accountants of Scotland.

 

Mr Fish currently has no beneficial interest in the share capital of the Company.

 

There are no other matters which are required to be announced with regard to the appointment of Mr Fish under paragraph (g) of Schedule 2 of the AIM Rules.

 

Michael Gerald Bourne, aged 55, is or has been a director or partner of the following companies during the previous five years:

 

Current Directorships / Partnerships:

Directorships / Partnerships held within the previous five years:

Accretion Capital LLP

MGB Technology Consulting Ltd

Coombe Wood Lawn Tennis Club Limited

Cygna Negra Limited

Cygna Negra Malta Limited

 

Mr Bourne currently has no beneficial interest in the share capital of the Company.

 

There are no other matters which are required to be announced with regard to the appointment of Mr Bourne under paragraph (g) of Schedule 2 of the AIM Rules.

 

 

Enquiries

 

Frontier IP Group Plc

0131 220 9491

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

020 7469 0935

Jon Levinson / Lucy Williams

KTZ Communications

020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

Notes to Editor:

 

Frontier IPspecialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes. www.frontierip.co.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADVLFLZXFEBBK
Date   Source Headline
18th Feb 20257:00 amRNS-RTopps Tiles launches Alusid’s Mas floor tiles
31st Dec 20241:30 pmRNSTotal Voting Rights
30th Dec 20249:56 amRNSHolding(s) in Company
20th Dec 20247:00 amRNSGrant of Options
19th Dec 20244:14 pmRNSResult of AGM
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20241:36 pmRNSHolding(s) in Company
27th Nov 20247:00 amRNSPosting of Circular & Annual Report, & AGM Notice
26th Nov 20247:00 amRNSResult of Retail Offer
22nd Nov 20241:31 pmRNSResult of Placing and Subscription
22nd Nov 20248:12 amRNSRetail Offer by PrimaryBid
22nd Nov 20247:01 amRNSProposed Placing and Subscription
22nd Nov 20247:00 amRNSFinal results for the year ended 30 June 2024
29th Oct 20244:45 pmRNSHolding(s) in Company
11th Sep 202412:10 pmRNSHolding(s) in Company
7th Aug 20243:52 pmRNSHolding(s) in Company
6th Aug 20243:47 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSPortfolio – Cambridge Raman Imaging loan facility
19th Jun 20247:00 amRNSHolding(s) in Company
24th May 20247:00 amRNSTopps Group’s arm launches Alusid floor tile range
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.